Immucell Corp (ICCC) is a publicly traded Healthcare sector company. As of May 21, 2026, ICCC trades at $9.88 with a market cap of $89.65M and a P/E ratio of -140.91. ICCC moved -4.90% today. Year to date, ICCC is +63.31%; over the trailing twelve months it is +78.34%. Its 52-week range spans $3.38 to $10.25. Rallies surfaces ICCC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in ICCC news today?
ImmuCell reports $10.4M Q1 sales, net income up 34% to $1.9M: ImmuCell posted record Q1 product sales of $10.4 million, up 28.4% year-over-year, driven by a 35.7% domestic gain to $9.7 million despite a 30.2% drop in international sales to $600,000. Gross margin improved to 45% and net income rose 34% to $1.9 million while cash on hand totaled $6.8 million.
te Boekhorst Paul Francis Olivier bought 2.43K (~$13.38K) on Dec 4, 2025.
te Boekhorst Paul Francis Olivier bought 3.60K (~$18.15K) on Dec 3, 2025.
te Boekhorst Paul Francis Olivier bought 2.56K (~$12.79K) on Dec 3, 2025.
ICCC Analyst Consensus
ICCC analyst coverage data. Average price target: $0.00.
Common questions about ICCC
What changed in ICCC news today?
ImmuCell reports $10.4M Q1 sales, net income up 34% to $1.9M: ImmuCell posted record Q1 product sales of $10.4 million, up 28.4% year-over-year, driven by a 35.7% domestic gain to $9.7 million despite a 30.2% drop in international sales to $600,000. Gross margin improved to 45% and net income rose 34% to $1.9 million while cash on hand totaled $6.8 million.
Does Rallies summarize ICCC news?
Yes. Rallies summarizes ICCC news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is ICCC research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ICCC. It does not provide personalized investment advice.
